195 related articles for article (PubMed ID: 33493414)
1. MicroRNAs Involved in Inflammatory Breast Cancer: Oncogene and Tumor Suppressors with Possible Targets.
Rezaei Z; Sadri F
DNA Cell Biol; 2021 Mar; 40(3):499-512. PubMed ID: 33493414
[TBL] [Abstract][Full Text] [Related]
2. miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness.
Lerebours F; Cizeron-Clairac G; Susini A; Vacher S; Mouret-Fourme E; Belichard C; Brain E; Alberini JL; Spyratos F; Lidereau R; Bieche I
Int J Cancer; 2013 Oct; 133(7):1614-23. PubMed ID: 23526361
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA function in cancer: oncogene or a tumor suppressor?
Shenouda SK; Alahari SK
Cancer Metastasis Rev; 2009 Dec; 28(3-4):369-78. PubMed ID: 20012925
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer and microRNAs: therapeutic impact.
Iorio MV; Casalini P; Piovan C; Braccioli L; Tagliabue E
Breast; 2011 Oct; 20 Suppl 3():S63-70. PubMed ID: 22015296
[TBL] [Abstract][Full Text] [Related]
5. Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers.
Mayr C; Beyreis M; Wagner A; Pichler M; Neureiter D; Kiesslich T
Biomed Res Int; 2016; 2016():4805270. PubMed ID: 27957497
[TBL] [Abstract][Full Text] [Related]
6. miRNome of inflammatory breast cancer.
Maltseva DV; Galatenko VV; Samatov TR; Zhikrivetskaya SO; Khaustova NA; Nechaev IN; Shkurnikov MU; Lebedev AE; Mityakina IA; Kaprin AD; Schumacher U; Tonevitsky AG
BMC Res Notes; 2014 Dec; 7():871. PubMed ID: 25471792
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential.
Wang W; Luo YP
J Zhejiang Univ Sci B; 2015 Jan; 16(1):18-31. PubMed ID: 25559952
[TBL] [Abstract][Full Text] [Related]
8. Circulating Cell-free miRNA Expression and its Association with Clinicopathologic Features in Inflammatory and Non- Inflammatory Breast Cancer.
Hamdi K; Blancato J; Goerlitz D; Islam M; Neili B; Abidi A; Gat A; Ayed FB; Chivi S; Loffredo C; Jillson I; Elgaaied AB; Marrakchi R
Asian Pac J Cancer Prev; 2016; 17(4):1801-10. PubMed ID: 27221856
[TBL] [Abstract][Full Text] [Related]
9. New insights into radioresistance in breast cancer identify a dual function of miR-122 as a tumor suppressor and oncomiR.
Perez-Añorve IX; Gonzalez-De la Rosa CH; Soto-Reyes E; Beltran-Anaya FO; Del Moral-Hernandez O; Salgado-Albarran M; Angeles-Zaragoza O; Gonzalez-Barrios JA; Landero-Huerta DA; Chavez-Saldaña M; Garcia-Carranca A; Villegas-Sepulveda N; Arechaga-Ocampo E
Mol Oncol; 2019 May; 13(5):1249-1267. PubMed ID: 30938061
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
11. MicroRNAs in Breast Cancer: Diagnostic and Therapeutic Potential.
Asiaf A; Ahmad ST; Arjumand W; Zargar MA
Methods Mol Biol; 2018; 1699():23-43. PubMed ID: 29086366
[TBL] [Abstract][Full Text] [Related]
12. [RNA interference: biogenesis molecular mechanisms and its applications in cervical cancer].
Peralta-Zaragoza O; Bermúdez-Morales VH; Madrid-Marina V
Rev Invest Clin; 2010; 62(1):63-80. PubMed ID: 20415061
[TBL] [Abstract][Full Text] [Related]
13. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer.
Svoronos AA; Engelman DM; Slack FJ
Cancer Res; 2016 Jul; 76(13):3666-70. PubMed ID: 27325641
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression and function in cancer.
Garzon R; Fabbri M; Cimmino A; Calin GA; Croce CM
Trends Mol Med; 2006 Dec; 12(12):580-7. PubMed ID: 17071139
[TBL] [Abstract][Full Text] [Related]
15. MetastamiRs: non-coding MicroRNAs driving cancer invasion and metastasis.
Lopez-Camarillo C; Marchat LA; Arechaga-Ocampo E; Perez-Plasencia C; Moral-Hernandez OD; Castaneda-Ortiz EJ; Rodriguez-Cuevas S
Int J Mol Sci; 2012; 13(2):1347-1379. PubMed ID: 22408395
[TBL] [Abstract][Full Text] [Related]
16. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
[TBL] [Abstract][Full Text] [Related]
17. The duality of oncomiR addiction in the maintenance and treatment of cancer.
Cheng CJ; Slack FJ
Cancer J; 2012; 18(3):232-7. PubMed ID: 22647359
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory breast cancer: an overview.
van Uden DJ; van Laarhoven HW; Westenberg AH; de Wilt JH; Blanken-Peeters CF
Crit Rev Oncol Hematol; 2015 Feb; 93(2):116-26. PubMed ID: 25459672
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs and metastasis: small RNAs play big roles.
Kim J; Yao F; Xiao Z; Sun Y; Ma L
Cancer Metastasis Rev; 2018 Mar; 37(1):5-15. PubMed ID: 29234933
[TBL] [Abstract][Full Text] [Related]
20. Novel miR-5582-5p functions as a tumor suppressor by inducing apoptosis and cell cycle arrest in cancer cells through direct targeting of GAB1, SHC1, and CDK2.
An HJ; Kwak SY; Yoo JO; Kim JS; Bae IH; Park MJ; Cho MY; Kim J; Han YH
Biochim Biophys Acta; 2016 Oct; 1862(10):1926-37. PubMed ID: 27475256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
